ArticleNAR genomics and bioinformatics2025
BreastSubtypeR: a unified R/Bioconductor package for intrinsic molecular subtyping in breast cancer research.
Article in NAR genomics and bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial.Nature communications · 2026Trial
- Development and validation of a machine learning clinicogenomic model to improve prognostic stratification in ER-positive/HER2-negative early breast cancer.Breast cancer research : BCR · 2026Article
- Genomic characterization of ER-positive primary tumors and corresponding relapses identifies potentially targetable alterations.NPJ breast cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intrinsic molecular subtyping (IS) of breast cancer is fundamental for understanding disease biology and guiding personalized treatment. While IS methods are standardized in clinical practice, their research implementations vary, leading to inconsistencies and reduced reproducibility. We introduce BreastSubtypeR, an R/Bioconductor package that unifies multiple published IS classifiers into a single, reproducible framework, enabling systematic cross-method comparison and robust cohort-aware selection. Its core feature, AUTO mode, quantitatively evaluates cohort composition and selectively activates classifiers whose assumptions are met, reducing user bias and improving robustness across skewed or subtype-specific cohorts. The package also provides a unified, method-specific normalization pipeline, optimized probe-to-gene mapping, and an intuitive local Shiny app (iBreastSubtypeR) for non-programmers. By standardizing method selection, preprocessing, and mapping within a Bioconductor workflow, BreastSubtypeR improves reproducibility and accessibility, and addresses an urgent need for assumption-aware IS in breast cancer research. Availability and implementation: The BreastSubtypeR package and its companion R Shiny application, iBreastSubtypeR, are freely available through Bioconductor (https://doi.org/10.18129/B9.bioc.BreastSubtypeR). The complete source code is also hosted on GitHub (https://github.com/JohanHartmanGroupBioteam/BreastSubtypeR). A citable archived snapshot of the version used (v1.1.3) is available on Zenodo (https://doi.org/10.5281/zenodo.17085316). The software is released under the GPL-3 license. Comprehensive documentation and an example dataset are provided to facilitate user adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.